All News

RheumNow Podcast square

Seronegative RA Disease Activity (7.17.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com.

Read Article
WashDC4.jpg

ACR: Medicare Cuts for Physicians Highlight Need for Reform

ACR

The American College of Rheumatology (ACR) was disappointed that the proposed Medicare Physician Fee Schedule (MPFS) from the Centers for Medicare & Medicaid Services (CMS) once again included a serious cut to the conversion factor.

Read Article
vitamins.png

ACP Position Paper on Dietary Supplements

Jack Cush, MD

More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.

Read Article
38420215_s.jpg

Guidelines to Spot Cancer in High Risk Dermatomyositis

MedPage Today

International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.

Read Article
RheumNow Podcast square

Gout Cavalcade (7.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article
Atyp.Fx_.jpg

Do we need Better Strategies to Prevent Osteoporotic Fractures?

Jack Cush, MD

In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.

Read Article
ILD damage fibrosis path

EULAR26: ANCHOR-RA Study of RA-ILD

EurekAlert!

People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality.

Read Article
Less than 10% of gout patients have crystal-proven gout. For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ,

Links:

Dr. John Cush RheumNow ( View Tweet)

CAR-T Therapy: EULAR 2026 Conference Recap https://t.co/XALrMFReOe https://t.co/TK0ot8MZb6

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA - a 120Year History Protecting Americans. Nice overview. - Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act - 1930 changed to Food and Drug Administration - 1938 Food, Drug, and Cosmetics Act - 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis. Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y

Links:

Dr. John Cush RheumNow ( View Tweet)
🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know. Watch now: https://t.co/KQmkdziLF5 #Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial https://t.co/ax0zwNcxYX
Dr. John Cush RheumNow ( View Tweet)
RheumIQ: Per the 2025 EULAR RA recommendations, if a csDMARD strategy fails, which drug class requires careful risk assessment before use? Test your knowledge this week at https://t.co/z8mLbcgE5D. https://t.co/r61gvyMHPS

Links:

Dr. John Cush RheumNow ( View Tweet)
2026 Guidelines for the Treatment of Axial Spondyloarthritis New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/3V8bfDptDU
Dr. John Cush RheumNow ( View Tweet)
EULAR26: GLP-1 Agonist Use in the RISE Registry At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). https://t.co/EqgETKjN1v
Dr. John Cush RheumNow ( View Tweet)
Insights into Treating Lupus - A Rheum Survey RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush RheumNow ( View Tweet)
RT @aurelierheumo What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects

Dr. John Cush RheumNow ( View Tweet)

RT @jiharheum MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. #EULAR2026 OP0206

Dr. John Cush RheumNow ( View Tweet)

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×